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Abstract
Processing of Gag polyproteins by viral protease (PR) leads to reorganization of immature retroviral particles and formation of a
ribonucleoprotein core. In some retroviruses, such as HIV and RSV, cleavage of a spacer peptide separating capsid and nucleocapsid
proteins is essential for the core formation. We show here that no similar spacer peptide is present in the capsid–nucleocapsid (CA–NC)
region of Mason–Pfizer monkey virus (M-PMV) and that the CA protein is cleaved in vitro by the PR within the major homology region
(MHR) and the NC protein in several sites at the N-terminus. The CA cleavage product was also identified shortly after penetration of
M-PMV into COS cells, suggesting that the protease-catalyzed cleavage is involved in core disintegration.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The structural proteins of retroviruses are synthesized in
the context of the Gag polyprotein with the general order
NH2–MA–CA–NC–COOH. Matrix protein (MA) was
found to be associated with the virus envelope glycopro-
teins, whereas the capsid (CA) protein forms a shell sur-
rounding the ribonucleoprotein complex consisting of viral
genomic RNA and nucleocapsid (NC) protein. Retroviral
CAs fold into two independent N- and C-terminal domains
separated by a flexible linker and exhibit a high degree of
structural similarity (Gitti et al., 1996; Gamble et al., 1997;
Berthet-Colominas et al., 1999; Jin et al., 1999; Kho-
rasanizadeh et al., 1999; Campos-Olivas et al., 2000; King-
ston et al., 2000; Cornilescu et al., 2001). Mutagenesis
studies have revealed that the N-terminal domain partici-
pates in capsid core formation and the C-terminal domain is
required for both assembly of immature capsids and the
mature viral core (Dorfman et al., 1994; Gamble et al.,
1997; Reicin et al., 1995). The C-terminal domain also
contains an evolutionary conserved subdomain, termed the
major homology region (MHR), which is critical for the
maintenance of the overall structure and for interactions
with other viral components and cellular factors (Wills and
Craven, 1991; Craven et al., 1995; Strambio-de-Castillia
and Hunter, 1992; Gamble et al., 1997). Despite extensive
knowledge of the role of CA protein in the process of
assembly of immature particles and formation of the core,
little is known about the process of disassembly of the
capsid core during the early phase of viral infection. How-
ever, the recently identified mutations, localized in various
surfaces of HIV-1 CA, confirmed that the core stability is
very sensitive to subtle structural alteration and that proper
disassembly of the viral core is essential for infectivity
(Forshey et al., 2002).
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In addition to structural proteins, short spacer peptide
(SP), separating CA and NC domains, was identified in
some retroviruses (Craven et al., 1993; Pepinsky et al.,
1995; Xiang et al., 2001; Henderson et al., 1987; Tobin et
al., 1994; Henderson et al., 1988; Ratner et al., 1987; Pettit
et al., 1994; Wiegers et al., 1998; Krausslich et al. 1995;
Gross et al., 2000; Shehu-Xhilaga et al., 2001). Although
there is no significant cross-species sequence identity be-
tween the spacer peptide sequences, the order of their pro-
teolytic cleavage in HIV-1 and RSV is similar (Pettit et al.,
1994; Accola et al., 1998; Wiegers et al., 1998; Craven et
al., 1993; Pepinsky et al., 1995). While the peptide bond
between the SP–NC is the first one to be cleaved within the
HIV-1 and RSV Gag polyproteins, the CA–SP site is the last
one to be cleaved during morphogenesis of these viruses.
Deletions or point mutations in SP sequences, as well as
preventing the cleavage within the HIV-1 and RSV SP
processing sites, result in morphologically aberrant parti-
cles, loss of infectivity, and gross aberrations in budding
(Go¨ttlinger et al., 1989; Pettit et al., 1994; Krausslich et al.,
1995; Accola et al., 1998; Craven et al., 1993; Pepinsky et
al., 1995; Xiang et al., 2001). There is no direct evidence of
of the existence of any “functionally relevant” SP region
within the M-PMV Gag sequence (Sonigo et al., 1986;
Bradac and Hunter, 1986a, 1986b; Henderson et al., 1985).
Here, we report that no spacer peptide separating the CA
and NC domains could be identified in M-PMV Gag polypro-
tein. We also show that, in addition to the previously published
cleavage site between CA and NC (Henderson et al., 1985), the
NC protein is in vitro further truncated at several sites within its
N-terminus. Moreover, we identified a novel unique cleavage
site within the MHR of M-PMV CA. Detection of similar CA
proteolytic product in mammalian cells shortly after infection
suggests that internal proteolytic cleavage of CA might be
involved in liberation of RNA from the ribonucleoprotein core
prior to reverse transcription. We also present evidence for
specific in vitro cleavage of HIV-1 CA by HIV-1 protease in at
least five sites. Although none of these sites falls into MHR
two lie within the regions important for the core stability
(Forshey et al., 2002).
Results
Protease-catalyzed cleavage of M-PMV CA–NC in vitro
The order and amino-terminal sequences of M-PMV Gag
structural proteins (Bradac and Hunter, 1986b; Henderson
et al., 1985) point to the CAQGLAM*AAAFSNC cleavage
site between M-PMV CA and NC domains. To investigate
the presence of an additional cleavage site that might be
involved in the processes occurring in the time period be-
tween virus release and reverse transcription, we performed
the in vitro cleavage of purified CA–NC fusion protein with
M-PMV protease. Products corresponding to specific cleav-
age of CA–NC between CA and NC were detected by both
SDS–PAGE (Fig. 1A) and Western blot analysis (Figs. 1B
and C) after 24 h of incubation with protease (Fig. 1A, lane
2; Fig. 1B, lane 1; Fig. 1C, lane 5). Additional protein of
electrophoretic mobility corresponding to 17 kDa, which
was recognized with anti-CA antibody, was detected after
48 h of incubation (Fig. 1C, lane 6) and its yield increased
with time (72 h, Fig. 1A, lane 4; Fig. 1C, lane 7). No
cleavage of CA–NC fusion protein was observed in either
control reaction mixtures containing (i) only CA–NC (Fig.
1A, lane 5; Fig. 1B, lane 3; Fig. 1C, lane 4) or (ii) CA–NC
incubated with protease in the presence of a specific M-
PMV PR inhibitor, ProTyrValPstAlaMetThr (Hrusˇkova´-
Heidingsfeldova´ et al., 1995) (data not shown).
M-PMV capsid protein is cleaved within major homology
region
To identify precisely the products of CA–NC digestion,
the cleavage mixture was first separated by RP-HPLC, and
fractions were analyzed by ESI-MS and N-terminal se-
quencing (see Table 1). The dominant peak corresponded to
the capsid protein. Its molecular mass 24,681 Da is in good
agreement with both its calculated mass 24,686 Da and the
mass of CA determined by analysis of M-PMV capsids
harvested from a recombinant baculovirus–insect cell ex-
pression system and cleaved with M-PMV protease, i.e.,
24,684 Da (Parker and Hunter, 2001). The amino acid
sequence PVTET corresponds to the N-terminal sequence
of CA (Henderson et al., 1985).
Cleavage of CA–NC yielded an additional CA product of
molecular mass of 17,226 Da. Edman degradation of this
product revealed the N-terminal sequence of CA, PVTET
(Table 1). Comparison of this experimentally determined mo-
lecular mass of the CA cleavage product with the calculations
based on the known CA sequence identified the fragment
spanning residues 1–158 (1PVTET . . . DEPFAD158).
The sequences derived from NC protein were found in
several RP-HPLC fractions, and the masses of the NC
fragments were in the range between 8,354 and 10,565 Da.
The majority of the products corresponded to the originally
published nontruncated N-terminus 1AAAFS. In addition,
8TVKDF, 12FLNNKN, and 17KNKEK N-terminal se-
quences were found as the minor components (Fig. 2).
Seventeen-kilodalton proteolytic product of M-PMV CA is
identical to that resulting from CA–NC cleavage
To verify the presence of the newly identified internal
cleavage site within the M-PMV CA domain, we performed
cleavage of isolated CA protein under conditions identical
to those described above for CA–NC fusion protein (Fig. 3).
Any nonspecific cleavage was observed in the reaction
mixture containing either CA alone (Fig. 3A, lane 6; Fig.
3B, lane 1) or CA with protease in the presence of a specific
protease inhibitor (Fig. 3A, lane 3; Fig. 3B, lane 2). The CA
cleavage product exhibited the same mobility on 15% SDS–
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PAGE gel (Fig. 3A, lane 5), reacted specifically with anti-
body against M-PMV CA (Fig. 3B, lane 3), and revealed the
identical amino acid sequence and similar molecular mass
(17,244 Da) as the corresponding CA–NC cleavage product.
The difference of 18 mass units could be ascribed to
oxidation of the Met residues within the CA sequence.
To confirm the internal cleavage site of the M-PMV CA,
a synthetic decapeptide, EPFADFVHRL, spanning the hy-
pothetic cleavage site 158D*F159 within the MHR, was used
as a substrate for M-PMV protease. Indeed, the products of
cleavage were identified by amino acid analysis as EPFAD
and FVHRL.
M-PMV CA cleavage product is present in infected
COS-1 cells
To study the internal cleavage of M-PMV CA in infected
cells, confluent COS cells were overlaid with radiolabeled
virions released from rhesus monkey CMMT cells. Viral
proteins were immunoprecipitated from cell lysates with
rabbit anti-CA (Fig. 4A) and anti-M-PMV antiserum (Fig.
4B). The full-length M-PMV capsid protein was present in
the lysates of COS cells within 2 h (Fig. 4A, lane 2; Fig. 4B,
lane 5). After 6 h, a band migrating at 17 kDa was recog-
nized both by the anti-CA (Fig. 4A, lane 3) and anti-M-
PMV rabbit antisera (Fig. 4B, lane 6). Antiserum against the
CA protein reacted specifically with other truncated CA
proteins with molecular weights of about 10 kDa which
might be the second moiety of CA after its cleavage (Fig.
4A, lane 3). However, this band was not observed in neither
Fig. 1. SDS–PAGE (A) and Western blot analysis (B, C) of proteolytic processing of CA–NC fusion protein. (A) Lane 1, M-PMV protease incubated for 72 h; lanes
2–4, proteolytic cleavage products of CA–NC incubated: 24 h (lane 2), 48 h (lane 3), 72 h (lane 4); lane 5, control CA–NC incubated 72 h without PR; lane 6,
molecular mass standards. The polyclonal rabbit antiserum against NC recognized only CA–NC and NC proteins (B) after 24 h (lane 1) and 48 h (lane 2) of
incubation with PR. Lane 3, CA–NC incubated without PR. The antiserum against CA reacted specifically with CA–NC, CA, and the 17-kDa cleavage product. (Fig.
1C). Lane 4, control sample of CA–NC incubated 72 h without PR; Lanes 5–7, CA-NC incubated with PR for 24 h (lane 5), 48 h (lane 6), and 72 h (lane 7).
Table 1
Masses and N-terminal sequences of HPLC-purified proteolytic
fragments of M-PMV capsid–nucleocapsid fusion protein
Fraction N-terminus
published/sequenced
Mass
determined/calculated
CA–NC *PVTET/PVTET 34080/34083
CA *PVTET/PVTET 24681/24686
NC *AAAFS/AAAFS 10563/10565
PR *WVQPI/WVQPI 12956/12955
CA fragment /PVTET 17226/17223
* See reference (Henderson et al., 1985; Bradac and Hunter, 1986b) for
originally determined sequence.
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the in vitro experiments or in the Western blot of the lysate
of infected cells using anti-M-PMV antiserum.
The corresponding CA cleavage product was not de-
tected in the released virions from CMMT cells (Fig. 4A,
lane 1; Fig. 4B, lane 4) where only the full-length capsid
protein was present. This demonstrates that the cleavage of
M-PMV CA protein by the viral protease occurs also in
mammalian cells in the early infection stage.
HIV-1 CA is cleaved by PR in vitro within N- and
C-terminal helixes
To determine whether internal proteolytic processing oc-
curs in CA of retroviruses of different morphogenetic type,
such as HIV-1, we cleaved HIV-1 CA by HIV-1 PR under
the in vitro conditions (see Material and Methods). Several
CA cleavage products were generated after 24 h of incuba-
tion, and even more extended proteolysis took place after
48 h of incubation (confirmed by the presence of several
fragments of lower molecular weight, data not shown).
Importantly, no detectable cleavage was found in control
experiments in which HIV-1 PR was either absent or inhib-
ited with its specific inhibitor, Saquinavir, indicating that
the observed cleavage was, indeed, PR dependent. Five PR
cleavage sites within the HIV-1 CA protein were then iden-
tified by a combination of MALDI-TOF mass spectrometry
and N-terminal sequencing: Ala22/Trp23, Ala78/Ala79,
Gly116/Trp117, L189/L190, and Ala204/Leu205. In order
to provide additional supporting evidence of susceptibil-
ity of these sites to proteolysis, the corresponding syn-
thetic decapeptides (of the general formula of P5–P5
with respect to the putative scissile bond P1–P1, see
Schechter and Berger, 1967 for nomenclature) were also
subjected to HIV-1 PR. We found that the enzyme selec-
tively cleaved only the predicted scissile peptide bond in all
five peptides.
Discussion
Ordered cleavage of the spacer peptide between CA and
NC domains is involved in morphological changes in the
late stage of life cycle of many retroviruses (Craven et al.,
1993; Pettit et al., 1994; Accola et al., 2000; Krausslich et
al., 1995). We sought to determine the presence of such a
spacer peptide within the M-PMV CA–NC region. Al-
though the analysis of products resulting from the in vitro
cleavage of purified bacterially expressed CA–NC fusion
protein revealed formation of wild-type NC (Henderson et
al., 1985) and several N-terminally truncated (by 7–16
Fig. 2. Amino acid sequence of M-PMV CA–NC. The originally published cleavage site between CA–NC (Henderson et al., 1985) is marked by an arrow; the
cleavage sites within the MHR region of CA and within the N-terminus of NC found after in vitro digestion of CA–NC fusion protein are designated by asterisks.
Fig. 3. SDS–PAGE and Western blot analysis of proteolytic processing of CA protein. M-PMV capsid protein was incubated with M-PMV PR for 24 h and
cleavage products were separated by SDS–PAGE (A) and analyzed by Western blot using polyclonal antibodies against CA (B). (A) Lane 1, molecular
markers; lane 2, CA stock solution; lane 3, CA incubated with PR and specific inhibitor; lane 4, CA with inhibitor; lane 5, CA with PR; lane 6, mere CA;
lane 7, M-PMV PR. (B) Lane 1, mere CA; lane 2, CA with PR and specific inhibitor; lane 3, CA with PR.
313M. Rumlova´ et al. / Virology 310 (2003) 310–318
amino acids) NC products, the N-terminal sequence analy-
sis of proteins of mature virions identified only the se-
quences published for CA and NC. This observation does
not suggest the presence of any spacer peptide separating
the CA and NC domains.
Importantly, during the in vitro cleavage of CA–NC, we
observed accumulation of a novel protein species of molec-
ular weight of about 17 kDa, which occurred parallel with
the generation of mature CA and NC. This species was
unambiguously identified as CA fragment [1–158]. We
were interested if this specifically processed CA product
could also be detected during the M-PMV life cycle. Indeed,
the 17-kDa cleavage fragment was observed in the cyto-
plasm of COS-1 cells shortly after their infection with
M-PMV. However, such CA-related truncated protein was
not detected in the released virions that were used for
infection, where only the full-length CA was present. The
time-dependent appearance of the CA cleavage product
within infected cells demonstrates that the internal cleavage
of CA occurs after or during entry of the virus into the cells
in the process of core disassembly. The M-PMV CA cleav-
age site, D158*F159, lies within the conserved MHR region
that is known as having an important role in the formation,
maintenance, and function of the core structure (Gamble et
al., 1997; Campos-Olivas et al., 2000). Mutagenesis studies
of MHR confirmed that subtle structural alterations influ-
ence the stability of the core (Cairns and Craven, 2001;
Bowzard et al., 2001); thus its desintegration via proteolysis
may trigger events leading to core disassembly. Interest-
ingly, Strambio-de-Castillia and Hunter (1992) observed the
presence of a cleavage product of CA of similar size (17
kDa) both in the cytoplasm and in the virions released from
COS-1 cells transfected with M-PMV CA mutant (D158Y)
which was shown to be noninfectious but nondefective in
particle assembly and release. The D158Y mutation co-
incides with the protease-processing P1 site within the
M-PMV MHR, and very likely, it increases the susceptibil-
ity of CA sequence to proteolysis prior to the reentry of the
virus into the cells.
Evidence for the involvement of CA in postentry repli-
cation events was reported also for murine leukemia virus
(Alin and Goff, 1996) and RSV (Cairns and Craven, 2001;
Bowzard et al., 2001). Alignment of the CA sequences of
different retroviruses in the MHR region (see Clish et al.,
1998) showed that the F167S mutation within the sequence
161SESFAD*FANRL171 in RSV CA, exhibiting a defect in
endogenous viral DNA synthesis, coincides with the pro-
tease-catalyzed cleavage site D158*F159 in M-PMV CA.
Since the substrate specificities of M-PMV and RSV pro-
teases are very similar (Hrusˇkova´-Heidingsfeldova´ et al.,
1995), one can expect that the cleavage of RSV CA within
the MHR during disassembly of the core would be compa-
rable to that of M-PMV.
In contrast to M-PMV CA, we characterized five cleav-
age sites within the bacterially expressed and purified
HIV-1 CA that are located outside of the MHR subdomain.
However, two of the HIV-1 CA mutations (N21A, K203A)
that were reported by Forshey et al. (2002) as destabilizing
the viral core and abolishing the infectivity occur in the P2
positions of the cleavage sites detected in our study. We
speculate that the mutations N21A, and K203A, adjacent to
the scissile peptide bond, could alter the susceptibility of the
sequences to processing by the viral protease and could
modulate the process of disassembly of the core.
In conclusion, the results described here represent indi-
rect evidence for the role of retroviral protease in the early
stage of the virus life cycle, probably during uncoating of
the core prior to reverse transcription. The correlation of
novel cleavage sequences with the phenotypically relevant
mutants affecting HIV core (N21A, K203A) and M-PMV
CA (D158Y) stability (Forshey et al., 2002; Strambio-de-
Castillia and Hunter, 1992, respectively) support this view.
Fig. 4. M-PMV-associated proteins in COS-1 cells early after the infection. Autoradiograph of metabolically labeled and immunoprecipitated proteins with
rabbit anti-CA (A) and anti-M-PMV (B) antiserum. Lanes 1 and 4, virions released from CMMT cells; lanes 2 and 5, COS-cell-associated viral proteins 2 h
after infection; lanes 3 and 6, COS-cell-associated viral proteins 6 h after infection. The arrows indicate CA and its cleavage products corresponding to relative
molecular weights of approximately 17 and 10 kDa.
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Material and methods
DNA constructs
All DNA manipulations were carried out by common
cloning techniques as described in Sambrook and Russel
(2001) and plasmid DNAs were propagated in Escherichia
coli DH5. All newly created constructs were verified by
DNA sequencing.
M-PMV CA was cloned by ligation of PCR amplified CA
region cleaved by NdeI–NcoI into the bacterial expression
vector pET22b also cleaved by NdeI–NcoI, as was described
in Rumlova´ et al. (2001).
M-PMV CANC encodes the M-PMV CA–NC fusion pro-
tein. Two oligonucleotides CAAAAGATCATATGCCA-
GTGACTGAAACCG and CAAACTCGAGCTATTAAT-
AAGCTTGTTTC carrying NdeI and XhoI sites, were used
to amplify the CA–NC fragment (from 1390 to 2356 nt in
M-PMV) by PCR. The fragment was cleaved at its termini
and cloned into pET22b (cut with NdeI and XhoI at 287 and
158 nt, respectively).
HIV CA encodes the CA region of HIV-1 Gag. Two
oligonucleotides, CAGCCAACATATGCCTATAGTG-
CAGAAC and CCAGATCTCGAGTCATTAATTAGC-
CTGTCTCTC, carrying NdeI and XhoI sites were used to
amplify the CA region of HIV-1 Gag. A 690-bp fragment
was cleaved by NdeI and XhoI and was then ligated into the
pET22b plasmid also cut with NdeI and XhoI.
Bacterial expression and protein purification
LB (Luria–Bertani) medium containing ampicillin (at a
final concentration of 100 g/ml) was inoculated with E.
coli BL21 (DE3) cells carrying the appropriate construct to
optical density OD590  0.1 and grown at 37°C. When the
cells reached OD590  0.6–0.8 the expression was induced
by addition of IPTG (isopropyl--D-thiogalactopyranoside)
to a final concentration of 0.4 mM. The cells were harvested
4 h postinduction by low-speed centrifugation and stored at
70°C.
Purification of M-PMV CA
Purification of M-PMV CA protein was performed as
described by Rumlova´ et al. (2001). Briefly, CA was solu-
bilized in 8 M urea and purified using gel filtration chro-
matography on Sephacryl S-100 HR column (Amersham
Pharmacia Biotech). After purification the CA protein was
refolded during three dialysis steps, concentrated by ultra-
filtration, and stored at 70°C.
Purification of CA–NC protein
The bacterial pellet obtained from 1 L of medium was
resuspended in 30 ml of buffer A (50 mM Tris–HCl, 150 mM
NaCl, 1 mM EDTA, 0.1% 2-mercaptoethanol, pH 8.0) con-
taining lysozyme and 200 l of cocktail inhibitor mix (Sigma)
and the mixture was stirred at room temperature for 30 min.
The cells were sonicated on ice and then incubated with so-
dium deoxycholate (DOC, 0.1% final concentration) for 30
min at 4°C. The cell lysate was then centrifuged at 10,000g
(Beckman JA-18 rotor) for 10 min. The supernatant (S1) was
kept on ice and the pellet was resuspended in buffer A con-
taining 0.5% Triton X-100 and 1 M NaCl and centrifuged at
10,000g (Beckman JA-18 rotor) for 10 min. The supernatant
(S2) was kept on ice and the pellet was again resuspended in
buffer A containing 0.5% Triton X-100, 1.5 M NaCl, and 0.1%
2-mercaptoethanol and centrifuged at 10,000g (Beckman
JA-18 rotor) for 10 min (supernatant S3). All supernatants (S1,
S2, S3) and the final pellet were analyzed by SDS–PAGE. The
supernatants S2 and S3 were combined and were dialyzed
against the buffer Z (50 mM phosphate, 500 mM NaCl, 0.1%
2-mercaptoethanol, pH 7.5) overnight at 4°C. The dialyzed
material was applied to a Zn2-chelating fast flow Sepharose
chromatography column (Amersham Pharmacia Biotech)
equilibrated in buffer Z. The CA–NC protein was selectively
bound to Zn–NTA through two zinc-finger motifs within the
M-PMV NC. The bound proteins were eluted with 2 M NH4Cl
in Buffer Z and fractions were analyzed by the SDS-PAGE.
The fractions containing CA-NC were combined and were
dialyzed against buffer B (50 mM Tris-HCl, 100 mM NaCl,
0.1% 2-mercaptoethanol, 1 M ZnCl2, pH 7.5) overnight at
4°C and the material was then applied to a phosphocellulose
column (Whatman). The CA-NC was eluted using linear NaCl
gradient (0–2 M NaCl in the buffer B) and the fractions were
analyzed by SDS-PAGE. The fractions containing CA-NC
were combined, dialyzed against buffer C (50 mM phosphate,
500 mM NaCl, 0.1% 2- mercaptoethanol, 1 M ZnCl2, pH
7.5), concentrated using ultrafiltration to 4 mg/ml, aliquoted
and stored at 70°C.
Purification of recombinant HIV-1 CA
Purification of HIV-1 CA was modified from the method
of Ehrlich et al. (1990). Briefly, the bacterial pellet obtained
from 1 L of culture medium was resuspended in buffer A
(50 mM Tris–HCl, 150 mM NaCl, 1 mM EDTA, 0.1%
2-mercaptoethanol, pH 8.0) containing lysozyme and cock-
tail inhibitor mix (Sigma) and the mixture was stirred at
room temperature for 30 min. The cells were sonicated on
ice and then incubated with DOC (0.1% final concentration)
for 30 min at 4°C. The cell lysate was then centrifuged at
14,000g (Beckman JA-18 rotor) for 20 min. The proteins
from the supernatant were precipitated with 10% ammo-
nium sulfate. The precipitate was collected by centrifuga-
tion at 14,000g (Beckman JA-18 rotor) for 20 min, at 4°C,
redissolved in 50 mM Tris–HCl (pH 8.0) buffer containing
30 mM NaCl and 1 mM EDTA, and dialyzed against the
same buffer overnight. The sample was then mixed with a
DEAE–Sephadex (approx. 1 mg of total protein and 1 ml of
ion exchanger). HIV-1 CA was precipitated from a flow
through portion with 50% ammonium sulfate, redissolved in
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buffer A, and applied to a Sephadex G-100 (470 ml) col-
umn. Fractions containing HIV-1 CA were concentrated to
4 mg/ml, aliquoted, and stored at 70°C.
HIV-1 and M-PMV proteases were cloned, expressed,
and purified as described by Weber et al. (1997) and
Za´bransky´ et al. (1998), respectively.
Cleavage of CA and CA–NC proteins in vitro
M-PMV protein stock solutions of CA and CA–NC were
diluted with 50 mM phosphate buffer, pH 6.2, containing 300
mM NaCl and 0.01% 2-mercaptoethanol to the concentrations
of 0.9 and 1.65 mg/ml, respectively, and were dialyzed against
the same buffer overnight at 4°C. Standard reaction mixtures
contained CA or CA–NC protein at a final concentration
33 M in a total volume 40 l and M-PMV protease at a final
concentration of 2 M. For inhibition of M-PMV PR,
2 M specific peptidomimetic inhibitor of the sequence
ProTyrValPstAlaMetThr (Hrusˇkova´-Heidingsfeldova´ et al.,
1995) was added to the reaction mixture.
HIV CA protein stock was diluted with 50 mM sodium
citrate buffer, pH 4.7, with 300 mM NaCl and 0.01% 2-mer-
captoethanol to the concentration 0.9 mg/ml and dialyzed
against the same buffer overnight at 4°C. Standard reaction
mixtures contained CA protein at a final concentration of 37
M in a total volume 40 l and HIV-1 protease at a
concentration of 2 M. Saquinavir, a specific HIV-1 pro-
tease inhibitor, at a final concentration of 2 M was added
to the control solutions.
All digestion mixtures were incubated at 37°C for the
desired time. Proteins were separated on the SDS–15%
polyacrylamide gels and stained with Coomassie blue G250
or blotted onto the nitrocellulose membrane and developed
immunochemically by using rabbit antibody against M-
PMV CA, M-PMV NC, or HIV-1 CA.
Cleavage of peptides
The cleavage of the peptides derived from M-PMV and
HIV-1 CA sequences was assayed by evaluation of the
cleavage products by RP-HPLC on a Vydac C18 RP column
in a methanol/H2O system. The peptides used in this study
were synthesized by the solid-phase method (Bodanszky
and Bodanszky, 1984), purified by RP-HPLC, and analyzed
by amino acid analysis and mass spectrometry. The standard
reaction conditions for the cleavage of peptides were as
follows: 50 mM sodium acetate, pH 5.3, 1 M NaCl, 0.05%
2-mercaptoethanol, 0.006 M EDTA, 330 M peptide, and
0.6 M protease in 120 l overnight at 37°C. The peptide
products generated by PR were characterized by amino acid
composition analysis.
N-terminal sequence analysis
To determine N-terminal sequences of the cleavage
products of M-PMV CA, CA–NC, and HIV-CA proteins,
polypeptide fragments were separated after digestion in
SDS–15% polyacrylamide gels, transferred to the poly(vi-
nylidene difluoride) (PVDF) membrane and stained with
Coomassie Blue R250. Automated Edman degradation of
proteins was carried out in an Applied Biosystems Procise
sequencer. The phenylthiohydantoins were identified by
HPLC on an Ultrasphere ODS column.
Reversed-phase high-pressure liquid chromatography
(RP-HPLC) purification of M-PMV CA–NC digest
fragments
The protease digest of CA–NC was acidified with formic
acid (to 25% v/v final concentration), and it was fractionated
by narrow-bore RP-HPLC on a Jupiter C4 silica column (5
m, 2.1  150 mm, Phenomenex, Torrance, CA) which
was developed using a gradient of acetonitrile in 0.08%
aqueous TFA (Kraft et al., 2000). Fractions absorbing at 210
nm were collected for N-terminal sequencing and mass
spectrometry analysis.
Mass spectrometry
The positive-ion matrix-assisted laser desorption ioniza-
tion time-of-flight mass spectrometry (MALDI-TOF MS)
analysis was performed using model ReflexIII delayed-ex-
traction MALDI-TOF mass spectrometer (Bruker Dalton-
ics) equipped with a 337-nm nitrogen laser; -cyano-4-
hydroxycinnamic acid or sinnapinic acid (MALDI-Quality,
Hewlett–Packard) was used as matrix. The instrument was
used in the linear mode of operation. The electrospray
ionization triple quadrupole mass spectrometry (ESI-MS)
analysis of HPLC-purified proteolytic fragments of M-PMV
was performed on model API3000 triple quadrupole mass
spectrometer (PE-Sciex,) equipped with a MicroIonSpray
electrospray source and operated in the positive mode. The
samples were reconstituted in 50% acetonitrile in 0.1%
acetic acid and were introduced at 5 l/min using a Harvard
Apparatus syringe.
Radiolabeling, immunoprecipitation, and gel
electrophoretic analysis of virus proteins
Confluent monolayers of rhesus monkey CMMT cells,
chronically infected with M-PMV, were incubated 30 min
in Cys, Met-free Dulbecco modified Eagle’s medium
(DMEM, Sigma) and then labeled overnight at 37°C in Cys,
Met labeling DMEM medium containing 35S-labeled me-
thionine and cysteine (60 Ci/ml) (ICN). The culture me-
dium containing radiolabeled virus particles, which were
released from the labeled cells, was collected and filtered
through 0.45 m polysulfone membrane (Whatman).
One microliter of polybrene (10 mg/ml) was added to 1
ml of the medium containing virions. COS-1 cells were
overlaid with the resulting mixture of radiolabeled viri-
ons and incubated for 2 h at 37°C. The cells were washed
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with PBS and complete DMEM was added. Cells were
lysed at different time points (1, 2, 4, and 6 h) in lysis
buffer A (0.05 M Tris–HCl, 1% Triton X-100, 1% so-
dium deoxycholate, 0.15 M NaCl, pH 7.5) containing
cocktail inhibitor mix 10 l/1 ml, DNase 7 g/ml, and
RNase 0.15 g/ml. SDS (0.1%) was added to the cell
lysate and cell-associated viral proteins were immuno-
precipitated with rabbit anti-CA and rabbit anti-M-PMV
antisera. Radiolabeled viral proteins were then separated
on SDS–15% polyacrylamide gel and detected by auto-
radiography.
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